(NASDAQ: RANI) Rani Therapeutics Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Rani Therapeutics Holdings's earnings in 2026 is -$29,442,000.On average, 6 Wall Street analysts forecast RANI's earnings for 2026 to be -$24,962,399, with the lowest RANI earnings forecast at -$36,421,565, and the highest RANI earnings forecast at -$10,406,161. On average, 6 Wall Street analysts forecast RANI's earnings for 2027 to be -$30,648,623, with the lowest RANI earnings forecast at -$38,849,669, and the highest RANI earnings forecast at -$23,413,863.
In 2028, RANI is forecast to generate -$32,853,738 in earnings, with the lowest earnings forecast at -$40,063,721 and the highest earnings forecast at -$28,616,944.